Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole versus risperidone for obsessive-compulsive symptoms in adults with bipolar disorder
IRCT20200614047761N1Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in obsessive compulsive disorder (OCD) and bipolar disorder (BD) comparing Aripiprazole with Risperidone (2 arms). Primary endpoint: Efficacy of treatment. Started Apr 2020; status: completed.
02
Drugs
aripiprazolerisperidone
03
Conditions
obsessive compulsive disorder (OCD)bipolar disorder (BD)
Beyond the preview
Go deeper on IRCT20200614047761N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200614047761N1.